STING-Activating Polymeric Nanovaccines for T Cell Therapy of Melanoma
用于黑色素瘤 T 细胞治疗的 STING 激活聚合物纳米疫苗
基本信息
- 批准号:9371064
- 负责人:
- 金额:$ 53.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-30 至 2022-08-31
- 项目状态:已结题
- 来源:
- 关键词:AdjuvantAnimalsAntigensCTLA4 geneCancer CenterCell TherapyCell physiologyClinicalClinical DataCombined Modality TherapyCytotoxic T-LymphocytesDendritic CellsDoseGoalsGuidelinesHistologyHuman PapillomavirusImmuneImmune checkpoint inhibitorImmune systemImmunocompetentIndividualInterferon ActivationInterferon Type ILarge Intestine CarcinomaLifeMC38Malignant NeoplasmsModelingMusMutateNanotechnologyNatureOrganPathway interactionsPatientsPeptidesPharmacology StudyPhasePolymersProductionProteinsProtocols documentationRefractoryResearch PersonnelSafetyT cell therapyT-LymphocyteTestingTherapeuticTissuesToxic effectTumor AntigensTumor ImmunityVaccinesarmcancer carecancer immunotherapycancer therapycheckpoint therapychemotherapyclinical translationcytokineimmune checkpointimmunogenicimmunotoxicityinhibitor/antagonistlymph nodesmelanomamembernanoparticlenanovaccineneoplasm immunotherapynovelpre-clinicalpreclinical evaluationprogramsresponsespatiotemporalsuccesssynergismsystemic toxicitytumortumor microenvironmentvaccine evaluation
项目摘要
Abstract
Cancer immunotherapy is emerging as a new paradigm for the treatment of cancer by targeting
the body's immune system instead of tumor. Clinical approvals of several check point inhibitors (e.g.,
Ipilimumab, Pembrolizumab) have shown durable response in a small subset of melanoma patients
over conventional chemotherapy. Despite these successes, many cancers are poorly immunogenic
and do not generate adequate cytotoxic T lymphocytes (CTLs) and therefore these patients cannot
benefit from immune checkpoint therapies. The long-term goal of this application is to establish
STING-activating polymeric nanovaccines for cytotoxic T cell therapy of melanoma. We will capitalize
on the discovery of an ultra-pH sensitive polymer (PC7A) that allows optimal spatio-temporal
orchestration of cytosolic delivery of tumor antigen (Ag) in dendritic cells and innate stimulation for the
robust production of tumor-specific CTLs. A simple physical mixture of Ag-PC7A NP resulted in a
robust Th1 and CTL (>80%) response without the need of innate stimulants (i.e., CpG, Poly(I:C)). Use
of tumor associated antigens (TAAs) have shown significantly increased antitumor efficacy in a
B16F10 melanoma model in mice. We will test the central hypothesis that PC7A nanoparticle vaccine
will synergize with checkpoint inhibition to allow a safe and efficacious T cell therapy of melanoma.
There are three specific aims: (1) Expand the nanovaccine platform to multiple melanoma peptide
antigens; (2) Evaluate the safety of the polymeric nanovaccines in healthy, immunocompetent
animals; and (3) Evaluate the antitumor efficacy of the polymer nanovaccines and its synergy with
checkpoint inhibition. Accomplishments of the above aims will provide critical data for clinical
translation of the nanovaccines for melanoma therapy. We will also collaborate with other
nanoalliance members to test the PC7A NP in additional cancer indications.
摘要
癌症免疫治疗正在成为通过靶向治疗癌症的新范式
而不是肿瘤。几种检查点抑制剂的临床批准(例如,
Ipilimumab,Pembrolizumab)在一小部分黑色素瘤患者中显示出持久的反应
而不是传统的化疗。尽管取得了这些成功,但许多癌症的免疫原性很差
并且不能产生足够的细胞毒性T淋巴细胞(CTL),
从免疫检查点疗法中获益。本申请的长期目标是建立
STING激活聚合物纳米疫苗用于黑色素瘤的细胞毒性T细胞治疗。我们将利用
发现了一种超pH敏感聚合物(PC 7A),
树突状细胞中肿瘤抗原(Ag)的胞质递送的协调和对肿瘤细胞的先天刺激
肿瘤特异性CTL的稳健产生。Ag-PC 7A NP的简单物理混合物产生了
稳健的Th 1和CTL(>80%)应答而不需要先天刺激物(即,CpG,Poly(I:C))。使用
的肿瘤相关抗原(TAA)已显示出显着增加的抗肿瘤疗效,
小鼠B16 F10黑色素瘤模型。我们将测试中心假设,即PC 7A纳米颗粒疫苗
将与检查点抑制协同作用,以允许黑色素瘤的安全和有效的T细胞疗法。
具体目标有三:(1)将纳米疫苗平台扩展到多种黑色素瘤肽
(2)评价聚合物纳米疫苗在健康、免疫活性
(3)评价聚合物纳米疫苗的抗肿瘤功效及其与药物的协同作用。
检查点抑制上述目标的实现将为临床提供关键数据
用于黑色素瘤治疗的纳米疫苗的翻译。我们还将与其他
nanoalliance成员测试PC 7A NP在其他癌症适应症中的作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jinming Gao其他文献
Jinming Gao的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jinming Gao', 18)}}的其他基金
STING Activating Synthetic Nanovaccine for HPV-Induced Cancers
STING 激活合成纳米疫苗治疗 HPV 诱发的癌症
- 批准号:
9892979 - 财政年份:2018
- 资助金额:
$ 53.55万 - 项目类别:
STING Activating Synthetic Nanovaccine for HPV-Induced Cancers
STING 激活合成纳米疫苗治疗 HPV 诱发的癌症
- 批准号:
10371057 - 财政年份:2018
- 资助金额:
$ 53.55万 - 项目类别:
STING Activating Synthetic Nanovaccine for HPV-Induced Cancers
STING 激活合成纳米疫苗治疗 HPV 诱发的癌症
- 批准号:
10113555 - 财政年份:2018
- 资助金额:
$ 53.55万 - 项目类别:
STING-Activating Polymeric Nanovaccines for T Cell Therapy of Melanoma
用于黑色素瘤 T 细胞治疗的 STING 激活聚合物纳米疫苗
- 批准号:
9982225 - 财政年份:2017
- 资助金额:
$ 53.55万 - 项目类别:
STING-Activating Polymeric Nanovaccines for T Cell Therapy of Melanoma
用于黑色素瘤 T 细胞治疗的 STING 激活聚合物纳米疫苗
- 批准号:
9754799 - 财政年份:2017
- 资助金额:
$ 53.55万 - 项目类别:
STING-Activating Polymeric Nanovaccines for T Cell Therapy of Melanoma
用于黑色素瘤 T 细胞治疗的 STING 激活聚合物纳米疫苗
- 批准号:
10229423 - 财政年份:2017
- 资助金额:
$ 53.55万 - 项目类别:
Ultra-Responsive "ON/OFF" Fluorescent Nanoprobes for Cancer Molecular Imaging
用于癌症分子成像的超响应“开/关”荧光纳米探针
- 批准号:
8705515 - 财政年份:2011
- 资助金额:
$ 53.55万 - 项目类别:
Ultra-Responsive "ON/OFF" Fluorescent Nanoprobes for Cancer Molecular Imaging
用于癌症分子成像的超响应“开/关”荧光纳米探针
- 批准号:
8193961 - 财政年份:2011
- 资助金额:
$ 53.55万 - 项目类别:
Ultra-Responsive "ON/OFF" Fluorescent Nanoprobes for Cancer Molecular Imaging
用于癌症分子成像的超响应“开/关”荧光纳米探针
- 批准号:
8516037 - 财政年份:2011
- 资助金额:
$ 53.55万 - 项目类别:
相似海外基金
The earliest exploration of land by animals: from trace fossils to numerical analyses
动物对陆地的最早探索:从痕迹化石到数值分析
- 批准号:
EP/Z000920/1 - 财政年份:2025
- 资助金额:
$ 53.55万 - 项目类别:
Fellowship
Animals and geopolitics in South Asian borderlands
南亚边境地区的动物和地缘政治
- 批准号:
FT230100276 - 财政年份:2024
- 资助金额:
$ 53.55万 - 项目类别:
ARC Future Fellowships
The function of the RNA methylome in animals
RNA甲基化组在动物中的功能
- 批准号:
MR/X024261/1 - 财政年份:2024
- 资助金额:
$ 53.55万 - 项目类别:
Fellowship
Ecological and phylogenomic insights into infectious diseases in animals
对动物传染病的生态学和系统发育学见解
- 批准号:
DE240100388 - 财政年份:2024
- 资助金额:
$ 53.55万 - 项目类别:
Discovery Early Career Researcher Award
Zootropolis: Multi-species archaeological, ecological and historical approaches to animals in Medieval urban Scotland
Zootropolis:苏格兰中世纪城市动物的多物种考古、生态和历史方法
- 批准号:
2889694 - 财政年份:2023
- 资助金额:
$ 53.55万 - 项目类别:
Studentship
Using novel modelling approaches to investigate the evolution of symmetry in early animals.
使用新颖的建模方法来研究早期动物的对称性进化。
- 批准号:
2842926 - 财政年份:2023
- 资助金额:
$ 53.55万 - 项目类别:
Studentship
Study of human late fetal lung tissue and 3D in vitro organoids to replace and reduce animals in lung developmental research
研究人类晚期胎儿肺组织和 3D 体外类器官在肺发育研究中替代和减少动物
- 批准号:
NC/X001644/1 - 财政年份:2023
- 资助金额:
$ 53.55万 - 项目类别:
Training Grant
RUI: Unilateral Lasing in Underwater Animals
RUI:水下动物的单侧激光攻击
- 批准号:
2337595 - 财政年份:2023
- 资助金额:
$ 53.55万 - 项目类别:
Continuing Grant
RUI:OSIB:The effects of high disease risk on uninfected animals
RUI:OSIB:高疾病风险对未感染动物的影响
- 批准号:
2232190 - 财政年份:2023
- 资助金额:
$ 53.55万 - 项目类别:
Continuing Grant
A method for identifying taxonomy of plants and animals in metagenomic samples
一种识别宏基因组样本中植物和动物分类的方法
- 批准号:
23K17514 - 财政年份:2023
- 资助金额:
$ 53.55万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)














{{item.name}}会员




